Investing, Markets & Money

In this eposode we're diving into Bitcoin and gold – exploring whether Bitcoin is really a new alternative to gold or something different altogether.

Join host Stuart Fieldhouse as he chats with Dovile Silenskyte, Director, Digital Assets Research at WisdomTree, uncovering why long-term holding beats market timing, how Bitcoin's volatility is changing, and what the future holds for these two macro assets in your portfolio.

Stay tuned for information to find out:

✔️Whether Bitcoin is still considered to be a volatile asset.
✔️Who's buying Bitcoin now and why.
✔️Whether Bitcoin will be a competitor to gold in the future.
✔️How current events are impacting the Bitcoin market.

And lots more.

You can find more information on WisdomTree's crypto ETFs here - https://www.wisdomtree.eu/en-gb

Sign up for The Armchair Trader free newsletter here - https://www.thearmchairtrader.com/new...

Chapters
01:20 Should you buy and hold bitcoin?
03:57 Are institutions buying bitcoin?
05:13 How does Bitcoin behave versus traditional assets?
07:00 Bitcoin versus Gold
11:24 Bitcoin exposure through ETFs
14:40 Stablecoins
15:15 Is Bitcoin going to replace fiat currency?
16:20 Bitcoin regulation

Is biotech finally back? In this episode, Stuart sits down with Ailsa Craig, co-manager of the International Biotechnology Trust from Schroders, a £1bn+ closed-ended fund with a 4% dividend yield and 30+ years of history, to break down everything self-directed investors need to know about the biotech sector right now.

They cover:
✅ Why biotech has been in a prolonged bear market (and why that's changing)
✅ The M&A wave sweeping the sector — and how IBT is benefiting
✅ FDA uncertainty under the new US administration
✅ AI's real (and realistic) impact on drug development timelines
✅ The pancreatic cancer breakthrough that could be approved within months
✅ Where the best risk-adjusted opportunities are in biotech today
✅ What could be the "next game-changing" moment for the sector?

Whether you're new to biotech investing or a seasoned investor looking for smarter sector exposure, this episode gives you a fund manager's inside view on one of the most complex - and rewarding - corners of the market.

🔔 Subscribe for more investing insights every week
👍 Like if you found this useful
💬 Drop your biotech related questions and comments below

LINKS & RESOURCES:
🔗 International Biotechnology Trust: https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/
🎙️ The Armchair Trader: https://www.thearmchairtrader.com

DISCLAIMER: This podcast is for informational and educational purposes only
and does not constitute financial advice. Always do your own research before
making investment decisions.

00:00 Introduction & welcome to Ailsa Craig
00:40 What is the International Biotechnology Trust?
02:28 How biotech boomed - and crashed - after COVID
05:35 Why the FDA matters so much to biotech investors
06:42 Innovation, ageing populations & unmet medical need
08:05 AI in drug development: hype vs. reality
10:06 Biotech strategies for investors
12:04 The "Biotech 2.0" opportunity: de-risked, commercial-stage companies
13:55 A wave of M&A activity this year
16:10 The pancreatic cancer breakthrough changing everything
18:55 What could be biotech's next game-changing moment?

Europe’s defence sector has entered a multi-year rearmament cycle — and investors are paying close attention.

In this episode of Investing, Markets & Money, we take a deep dive into the European defence industry, exploring how rising military budgets, geopolitical risk, and industrial collaboration are reshaping the sector.

Our guest, Aneeka Gupta, Director of Macro Research at WisdomTree , explains:

- Why European defence spending is accelerating
- How long-term contracts and order backlogs are driving earnings growth
- The role of IPOs and smaller specialist defence companies
- Why air & missile defence, cyber security, and ammunition are key growth areas
- How European defence stocks compare to US peers on growth and valuation
- Whether defence investing can now fit within ESG frameworks

We also discuss supply-chain constraints, collaboration across Europe, and why this rearmament cycle could last far longer than many investors expect.

📌 This podcast is for information and entertainment purposes only and does not constitute financial advice.

👉 Subscribe for more expert interviews on markets, ETFs, commodities, and global investment themes.

#Investing #StockMarket #DefenseStocks #GlobalMarkets #CapitalMarkets #EuropeanDefence
#DefenceIndustry #AerospaceAndDefence #EuropeanStocks #EUInvesting #Geopolitics
#CyberSecurity #MilitarySpending #DefenseETFs #LongTermInvesting

Follow us:
BlueSky - https://bsky.app/profile/thearmchairtrader.com
Linkedin - https://www.linkedin.com/company/10429893
Instagram - https://www.instagram.com/armchairtrader
Facebook - https://www.facebook.com/TheArmchairTrader

In this episode of the Investing, Markets & Money Podcast, host Stuart Fieldhouse is joined by Bruce MacLachlan, President & COO of Bold Ventures.

We discuss Bold Ventures’ active drill program in Ontario, including its flagship Burchell Lake Project, located close to a 6 million ounce gold system. Bruce shares details on recent drilling, high-grade gold samples, and what investors should watch for as assays come back over the coming months.

We also cover:

- Why sentiment at PDAC is improving in 2026
- Bold’s exposure to gold, copper, zinc, nickel & critical minerals
- The long-term optionality of the Ring of Fire, including Bold’s carried interest in chromite
- How management prioritises capital while limiting shareholder dilution
- Near-term catalysts and what could drive valuation going forward

This is a must-listen interview for junior mining and resource investors looking for leverage to gold and critical minerals in a strengthening market.

In the latest episode of the Investing Markets and Money podcast, Drew Clark, CEO of Summit Royalties (TSXV:SUM), discusses the explosive growth of his company and why the royalty model remains the "most beautiful part" of the mining industry. Since its public debut just four months ago, Summit has rapidly transformed from a startup with minimal capital into a diversified powerhouse with over 50 royalties in its portfolio.

Find out more about Summit Royalties here - https://www.summit-royalties.com/

Sign up to The Armchair Trader free newsletter here - https://www.thearmchairtrader.com/newsletter/

Listen on:
Spotify - https://open.spotify.com/show/2vfaIsYhqcRejpjWNqYF6f
Apple Podcasts - https://podcasts.apple.com/gb/podcast/the-armchair-trader-podcast/id1454640070
Amazon - https://music.amazon.co.uk/podcasts/68a66097-24d8-403e-a86f-70fab0d2d686/The-Armchair-Trader-Podcast
SoundCloud - https://soundcloud.com/armchairtrader/

Follow us:
BlueSky - https://bsky.app/profile/thearmchairtrader.com
Linkedin - https://www.linkedin.com/company/10429893
Instagram - https://www.instagram.com/armchairtrader
Facebook - https://www.facebook.com/TheArmchairTrader

00:00 What are mining royalties?
02:57 Intro to Summit Royalties
04:37 How have Summit grown so quickly?
05:39 Which are the key assets in the portfolio?
08:49 The Saddle North project
09:03 How major is the Star Royalties project?
10:12 What kind of projects do Summit look for?
12:46 Precious Metals outlook
14:17 Importance of networking
15:09 Future plans for Summit Royalties
15:27 The attraction of the royalty model